SUPN vs. PCRX, INVA, ARQT, OCUL, ORIC, PHAT, CORT, KPTI, BTAI, and PRGO
Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Pacira BioSciences (PCRX), Innoviva (INVA), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Corcept Therapeutics (CORT), Karyopharm Therapeutics (KPTI), BioXcel Therapeutics (BTAI), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.
In the previous week, Pacira BioSciences had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 4 mentions for Pacira BioSciences and 2 mentions for Supernus Pharmaceuticals. Pacira BioSciences' average media sentiment score of 0.93 beat Supernus Pharmaceuticals' score of 0.34 indicating that Pacira BioSciences is being referred to more favorably in the news media.
99.7% of Pacira BioSciences shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Supernus Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500.
Pacira BioSciences received 339 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.81% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has a net margin of 10.34% compared to Supernus Pharmaceuticals' net margin of -2.60%. Pacira BioSciences' return on equity of 12.98% beat Supernus Pharmaceuticals' return on equity.
Supernus Pharmaceuticals presently has a consensus target price of $41.00, indicating a potential upside of 40.89%. Pacira BioSciences has a consensus target price of $47.40, indicating a potential upside of 53.80%. Given Pacira BioSciences' higher possible upside, analysts plainly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.
Summary
Pacira BioSciences beats Supernus Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Supernus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Supernus Pharmaceuticals Competitors List
Related Companies and Tools
